Diamond Sponsors 2018



DIAMOND SPONSORS

At Abbott, we're committed to helping you live your best possible life through the power of health. For more than 125 years, we've brought new products and technologies to the world — in nutrition, diagnostics, medical devices and branded generic pharmaceuticals — that create more possibilities for more people at all stages of life. Today, 94,000 of us are working to help people live not just longer, but better, in the more than 150 countries we serve.
 
Connect with us at www.abbott.com, on Facebook at www.facebook.com/Abbott and on Twitter @AbbottNews and @AbbottGlobal.

 

Adamas uses its deep understanding of time-dependent biology to redefine the treatment experience for patients suffering from chronic neurological diseases. Building upon the commercial launch of GOCOVRI™  (amantadine) extended release capsules (previously ADS-5102), the first and only FDA-approved medicine for the treatment of dyskinesia in patients with Parkinson’s disease receiving levodopa-based therapy, with or without concomitant dopaminergic medications and its advancing  pipeline of differentiated investigational programs, which includes ADS-5102 in development for the treatment of multiple sclerosis walking impairment; and ADS-4101, a high-dose, modified-release lacosamide in development for the treatment of partial onset seizures in patients with epilepsy, Adamas’ goal is to create and commercialize a new generation of medicines intended to lessen the burden of disease on patients, caregivers and society. Its unique expertise lies in uncovering and mapping the relationship between disease and drug activity to create medicines with therapeutic profiles that match the pattern of disease to drive a highly significant and durable clinical effect. This understanding of time-dependent biological processes informs every innovation, targeting advancement in treatment of chronic neurologic disorders. For more information, please visit www.adamaspharma.com.

 

Lundbeck, a global pharmaceutical company based in Denmark and founded in 1915, strives for global leadership in psychiatry and neurology by improving the lives of patients.  One of the world’s leading companies specializing in brain disorders, Lundbeck is focused on innovating treatments for depression, schizophrenia, Parkinson’s disease and Alzheimer’s disease.

To learn more, visit us at www.LundbeckUS.com and connect with us on Twitter at @LundbeckUS.

 

At UCB, everything we do starts with a simple question: “How will this make a difference to the lives of people living with severe diseases?” We have a passionate, long-term commitment to discovering and developing innovative medicines that transform the lives of people living with severe diseases of the immune system and the central nervous system. We do that by connecting with patients and their families around the world living with the physical and social burdens of severe disease. Those connections offer new perspectives, drive innovation, and offer the hope of a new generation of therapies that are helping to transform lives. With a team of approximately 7,500 employees and operations in more than 40 countries, we are a global biopharmaceutical company investing approximately 27% of revenue in cutting-edge scientific research to meet unmet patient needs. The company is based in Brussels, Belgium, with U.S. headquarters located in Atlanta, Georgia. Follow us on Twitter: @UCB_news